CClinicalTrials.gg
CompletedNCT06965816Updated May 11, 2025

Using Neuroimaging to Early Diagnose Alzheimer's Disease Through Hippocampal Atrophy Assessment

An observational study in Alzheimer's Disease, Hippocampus and Brain Atrophy, sponsored by Centre Hospitalier de Saint-Denis. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by Centre Hospitalier de Saint-Denis · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
85
Sex
All
01

Study summary

This study aims to better understand Alzheimer's disease by looking at brain scans, specifically MRI images, to detect early signs of brain changes linked to the disease. Researchers are focusing on the hippocampus, a part of the brain that shrinks in people with Alzheimer's. The study will also explore other brain changes that often happen alongside hippocampal shrinkage. By analyzing these brain images, the study hopes to find ways to diagnose Alzheimer's earlier and more accurately using advanced imaging techniques.

02

Conditions studied

  • Alzheimer's Disease
  • Hippocampus
  • Brain Atrophy
  • Magnetic Resonance Imaging
  • Leukoaraiosis
  • Neurodegenerative Diseases
  • Cortical and Subcortical Atrophy
03

In context

Alzheimer Disease

3,678 studies on the registry are indexed under Alzheimer Disease; 872 are open to participants now.

This study's enrollment of 85 is below the median of 200 across 751 observational studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

Centre Hospitalier de Saint-Denis is the lead sponsor of 42 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be selected from a retrospective cohort of patients who underwent brain MRI scans (3D T1 Bravo and Cube FLAIR sequences) between January 2018 and June 2022. The study population includes two groups: patients diagnosed with Alzheimer's disease based on clinical and biological assessments, and cognitively healthy individuals with no history of neurological or psychiatric disorders, serving as controls.

Inclusion criteria

  • Patients who underwent a brain MRI (3D T1 Bravo and Cube FLAIR sequences) between January 2018 and June 2022.
  • Diagnosis of Alzheimer's disease (for the Alzheimer group).
  • No neurological disease for control group participants.
  • Complete clinical and biological assessments available.
  • Quality imaging without motion artifacts.

Exclusion criteria

Exclusion Criteria:

  • Incomplete clinical or radiological data.
  • Poor image quality (e.g., motion artifacts).
  • Presence of other neurodegenerative or psychiatric disorders.
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
85 participants (actual)
Patient registry
No

Groups and cohorts

  • Alzheimer Group

    Alzheimer's patients

  • Control Group

    Unreached witnesses

06

What researchers measure

Primary outcomes

  1. Hippocampal Volume Measured by 3D MRI

    Objective volumetric measurement of the right and left hippocampus using 3D T1 Bravo MRI sequences, allowing quantification of hippocampal atrophy.

    Time frame: Retrospective analysis between January 2018 and June 2022

07

Study locations

1 site
  • France
    Saint Denis, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06965816
Lead sponsor
Centre Hospitalier de Saint-Denis
Responsible party
Sponsor
First posted
May 11, 2025
Start date
Nov 24, 2022
Primary completion
May 24, 2023
Completion
May 24, 2023
Last update
May 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion